Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Buckler, H.M.
Right arrow Articles by Lambert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buckler, H.M.
Right arrow Articles by Lambert, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 12, 2969-2973, December 1999
© 1999 European Society of Human Reproduction and Embryology

Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon)

H.M. Buckler1, W.R. Robertson2, A. Anderson1, M. Vickers1 and A. Lambert2,3

1 Department of Medicine, Hope Hospital, Salford and 2 Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK

We investigated whether a recombinant follicle stimulating hormone (FSH) (Puregon®) can be administered less frequently and at lower doses during ovulation induction than is current practice. Patients (20–35 years, body mass index <30 kg/m2) with infertility and chronic anovulation secondary to polycystic ovarian syndrome and resistant to previous clomiphene treatment received (Puregon®; 100 IU, n = 17 patients, or 50 IU, n = 10 patients) on alternate days. After 2 weeks and in the absence of follicular recruitment, doses were increased stepwise at weekly intervals (50 IU/alternate days). Twenty-two cycles out of 27 were ovulatory. There were six pregnancies, five from Puregon® (100 IU) and one from Puregon® (50 IU); four pregnancies proceeded to term. The duration of stimulation (mean, range) with Puregon® (100 IU) was 16.4, 7–29 and Puregon® (50 IU) 19.1, 8–38 days. The gonadotrophin doses administered (mean; range) were 689, 200–1800 IU (Puregon® 50 IU) and 939, 400–2300 IU (Puregon® 100 IU). We conclude that low dose alternate day Puregon® treatment is suitable for this difficult patient group.

Key words: ovulation induction/Puregon®/recombinant FSH

3 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
G. Ragni, F. Alagna, C. Brigante, A. Riccaboni, M. Colombo, E. Somigliana, and P.G. Crosignani
GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages
Hum. Reprod., January 1, 2004; 19(1): 54 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Balasch, F. Fabregues, M. Creus, B. Puerto, J. Penarrubia, and J. A. Vanrell
Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens
Hum. Reprod., April 1, 2001; 16(4): 652 - 656.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.